Solvay ups bid for Innogenetics

It looks like Solvay, not Gen-Probe, will be buying Belgium's Innogenetics. Back in April Solvay made a $278.2 million (€177.6 million) takeover bid for the company, but San Diego-based Gen-Probe trumped that offer, pledging $334 million for Innogenetics. That meant Innogenetics would get $9.58 per share, but Solvay has now offered $10.22. Gen-Probe won't pursue the deal, saying that a higher offer doesn't make financial sense for the company.

When it first pursued a buyout back in April, Solvay said it was looking to expand the company's diagnostics business. Solvay and Gen-Probe have been R&D partners since 1997; Solvay is the company's second largest shareholder.

- check out the report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.